Getting the levothyroxine (LT4) dose right for adults with hypothyroidism: opportunities and challenges in the use of modern LT4 preparations

Curr Med Res Opin. 2022 Nov;38(11):1865-1870. doi: 10.1080/03007995.2022.2071059. Epub 2022 May 12.

Abstract

Lifelong treatment with levothyroxine (LT4) is the mainstay of management for individuals with hypothyroidism. Many hypothyroid patients start LT4 treatment at a low dose (e.g. 25-50 µg), especially the elderly, those with residual thyroid function, those with low body weight, and those with significant (especially cardiac) comorbidities. Almost half of patients on LT4 replacement therapy demonstrate either under- or over-treatment. Many LT4 preparations have relatively large intervals between tablet strengths at the lower end of their dose ranges (providing 25 µg, 50 µg, and 75 µg tablets), which may represent a barrier to achieving the optimum maintenance treatment for some patients. The availability of intermediate tablet strengths of LT4 in the 25-75 µg range may facilitate precise and effective dose titration of LT4 and may also enable convenient maintenance regimens based on a single LT4 tablet daily, to support adherence to therapy.

Keywords: Dose titration; Hypothyroidism; Levothyroxine; Treatment adherence.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Hormone Replacement Therapy
  • Humans
  • Hypothyroidism* / drug therapy
  • Tablets / therapeutic use
  • Thyrotropin
  • Thyroxine* / therapeutic use

Substances

  • Thyroxine
  • Tablets
  • Thyrotropin